This work is likely to have general relevance in these conditions too. Schewitz-Bowers, L. Lee, R. Schewitz, L. Dayan, C. Creed, L. Schewitz, P. Newcomb, L. Nicholson, A. Dick, and C. References Schewitz-Bowers, L. These effects include analgesia and inhibition of adhesion molecule expression. The genomic effects are mediated via the corticosteroid receptor CR whose principal functions of transactivation, DNA binding and ligand binding are localized to specific DNA domains [ 9 ]. Alternative splicing of mRNA results in a number of isoforms Fig.
However, there are conflicting data refuting this role [ 23 , 24 ]. The CR-P isoform is encoded for by exons 2—7 plus several base pairs from the subsequent intron region [ 26 ]. This isoform lacks the ligand-binding domain and therefore cannot bind corticosteroids. Its function is unknown. CR-A results from excision of exons 5—7, resulting in juxtaposition of exons 8 to 4; its function is unknown [ 26 ].
GRE can mediate both positive and negative corticosteroid effects [ 30 , 31 ] Fig. Receptor dissociates from the inactive, multi-protein complex. GRE can mediate both positive and negative corticosteroid effects. Histone acetylation is regulated by a balance between the activity of histone acetyltransferases HATs and histone deacetylases HDACs which reverses the process, leading to gene repression [ 44 ]. Corticosteroids also induce apoptosis of lymphocytes and thymocytes, but these effects may be secondary to the inhibition of cytokine growth and proliferation factors.
The activity of the pro-inflammatory kinase cascade systems, such as the extracellular regulated kinase ERK and JNK mitogen-activated kinases MAPKs [ 48—51 ] are modulated by corticosteroids. For instance, it has recently been shown that corticosteroids induce the sustained expression of MAPK phosphatase 1 MKP-1 which inhibits the MAPK signalling pathways by dephosphorylating proteins [ 52 , 53 ]. Corticosteroids induce the production of MKP-1 which potently inactivates phosphorylated MAPK p38 leading to the destabilization of pro-inflammatory mRNAs by corticosteroids [ 52 , 53 , 56 , 57 ].
Finally, corticosteroids also induce the production of lipocortin, an anti-inflammatory protein made by peripheral blood mononuclear cells which mediates a number of corticosteroid effects. The regulation of gene expression also requires an orchestrated and coordinated control of the cross-talk between transcription factors to regulated transcriptional, post-transcriptional, translational and post-translational events.
These mechanisms are all modulated by corticosteroids. The body needs to regulate the biological effects of corticosteroids. The mechanisms involved in the regulation of corticosteroid effects include alterations in the bioavailability of corticosteroids within the respective microenvironment of the target tissues and counter-regulation by pro-inflammatory cytokines and hormones.
Factors such as route of administration may be important in determining corticosteroid bioavailability and bioactivity. For instance, malabsorption of orally administered steroid may cause a failure to respond to therapy in some patients with small bowel disease given enteric-coated corticosteroid preparations.
Nevertheless, corticosteroids pass through the cell membrane well. In humans, BHD exists as two isoenzymes type 1 and type 2 [ 59 ]. The type 2 BHD inactivates cortisol by converting it to cortisone which is not bioactive, whilst the type 1 isoenzyme converts cortisone to cortisol, and thus may amplify the biological activity of corticosteroids [ 59 ]. MIF down-regulates the immunosuppressive effects of corticosteroids [ 5 ].
The exact mechanisms have not been fully characterized. PLA2 is a key target of the anti-inflammatory actions of corticosteroids. MIF regulates IL-2 secretion and T-cell proliferation [ 60 ], which may in part be mediated via increased cellular expression of prolactin [ 4 ]. Essentially, hormones may be divided into anti-inflammatory hormones, such as cortisol and melatonin, and pro-inflammatory hormones, such as CRH, prolactin, arginine vasopressin and substance P [ 3 , 4 , 61 , 62—73 ].
The biological effects of prolactin have been studied more extensively. Prolactin, like MIF, is produced by the pituitary gland and peripheral blood mononuclear cells and antagonizes the effects of corticosteroids in vivo and in vitro [ 4 , 62—65 ]. It is an essential co-mitogen for T and B cells and can activate natural killer NK cells and macrophages [ 57 , 68 ]. Prolactin is essential for IL-2 and IL-2R expression, is an important pre-requisite for T-cell proliferation and enhances gamma-interferon production [ 67 , 69 , 70 ].
At the molecular level, prolactin exerts its effects via prolactin receptors found on macrophages and T and B cells [ 71 ]. The coupling of the hormone to the prolactin receptors activates the JAK family of kinases which in turn phosphorylate and activate STAT5 [ 72—74 ]. This pathway leads to increased levels of AP-1 [ 79 ]. Thus, prolactin modulates corticosteroid responsiveness by enhancing cell proliferation and survival [ 83 ]. Corticosteroids are used to treat a variety of inflammatory conditions which include asthma, inflammatory bowel disease, chronic autoimmune inflammatory renal, skin and rheumatic diseases as well as being part of immunosuppressive therapy regimes for organ transplant rejection and chemotherapy treatment regimes.
The failure of therapeutic corticosteroid doses to inhibit inflammatory disease in a number of conditions such as RA, asthma and inflammatory bowel disease has been intriguing. In RA patients, this resistance to corticosteroids appears not to be related to disease severity as measured by clinical parameters. Interestingly, it can also be seen in normal individuals [ 14 , 84—86 , 88 ], suggesting that it may be an intrinsic property of the individual [ 14 ] which may, therefore, have a genetic basis.
Interestingly, the ALL cells appear to acquire resistance to corticosteroids during therapy, but this could reflect positive selection of steroid-resistant mutant leukaemic cells that fail to undergo apoptosis [ 89 ]. The molecular basis of corticosteroid resistance in RA patients remains largely unknown but may be related in part to perturbations and dysregulation of some of the known cellular and molecular mechanisms of corticosteroid action.
It is not yet clear whether different mechanisms operate in different individuals or diseases or whether the SR phenomenon seen in RA patients is primary or secondary. The SR mechanisms have also been studied in asthma patients who are not responsive to corticosteroids.
Some of the mechanisms observed in asthma patients are of relevance to the phenomenon of corticosteroid resistance seen in some patients with rheumatoid arthritis. In Vingerhoeds et al. They reported a case of cortisol resistance in which high circulating cortisol blood levels were not associated with Cushing's syndrome but appeared to be related to a ligand affinity defect of the corticosteroid receptor. This family has been re-studied and a defect in the affinity of corticosteroid receptor for cortisol was demonstrated [ 91 , 92 ].
Polymorphic alterations in the CR gene were proposed as the underlying molecular basis of SR in this family. The term primary SR was coined. In a subsequent study, Huizenga et al. This suggests that alterations somewhere in the cascade of events starting with ligand binding to the receptor, or alterations in the regulation of the expression of corticosteroid responsive genes, or post-receptor defects of interaction with other nuclear factors form the pathophysiological basis of the corticosteroid resistance.
Such a systematic dissection of a genetically based study has not been performed in SR RA patients. Its demonstration has, however, many pathophysiological and therapeutic implications. The SS and SR phenotype appears to be stable when tested repeatedly over time in RA patients and normal subjects, suggesting that it may be an intrinsic property of the individual that is not necessarily acquired as a consequence of prolonged inflammation per se [ 14 ].
Lymphocytes from RA patients have decreased numbers of corticosteroid receptors but this does not result in a significant reduction of cell sensitivity to dexamethasone in vitro [ 94 ]. However, alterations in the expression of the CR isoforms may potentially contribute to a state of reduced corticosteroid responsiveness in patients with RA. Perturbations of the relative levels of expression of the various chaperone and co-chaperone proteins could potentially contribute to the SR phenomenon.
A similar mechanism has been shown for Hsp90 [ ]. The potential role played by defects in these chaperone proteins remains to be determined in RA, but nevertheless, investigation of these modifications in SR RA patients promises to be a particularly rich field for future scientific research. The functional status of cellular receptors is generally regulated by phosphorylation and nitrosylation mechanisms. Corticosteroid receptors, like other steroid hormone receptors, are phosphoproteins and changes in their phosphorylation status modulate their activity.
Several of the phosphorylation sites lie in the consensus sequences of proline-directed, cell-cycle-associated kinases and MAPK. This supposition is supported by the observation that defects in the phosphorylation of the rat corticosteroid receptor inhibit corticosteroid-dependent gene transcription [ ]. The inhibitory interactions involved in transrepression are mutual see above.
Cells from SR asthma patients have been shown to have enhanced AP-1 activity [ ] and phosphorylation of JNK not inhibited by corticosteroids [ ]. In asthma patients, p38 MAPK-induced glucocorticoid receptor phosphorylation reduces its activity and has a role in reduced corticosteroid sensitivity. This may also be of relevance to the SR phenomenon seen in RA. Thus, over-expression of activated STAT5, which could be secondary to prolactin over-expression, diminishes the induction of corticosteroid-responsive genes and contributes to a state of reduced corticosteroid responsiveness.
These mechanisms may be of relevance to the SR phenomenon in RA patients. We are at present investigating these possibilities. MIF inhibits the effects of corticosteroids see above. Similar observations have been made in SR asthma patients with respect to IL-2 secretion [ ].
A defect in corticosteroid-induced IL secretion has been observed in SR asthma patients [ ]. The molecular pathways through which corticosteroids act are complex and involve multiple steps involving the cell membrane, steroid receptors, intracellular signalling pathways and interactions with the DNA and RNA machinery. Corticosteroid resistance may develop as a consequence of perturbation s at any point in the pathway.
Unresponsiveness to corticosteroid therapy is a major therapeutic challenge in patients with RA. Finally, alterations in the bioavailability of corticosteroid may also play a part, and these remain to be determined. The full understanding of the molecular basis of SR in RA patients will lead to the development of more rational therapeutic strategies.
The authors would like to thank the Arthritis Research Campaign UK for support and Rukshana Patel for administrative and technical input and support. Van Den Berg WB. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum ; 30 Suppl 2 : 7 — Chikanza IC, Grossman A. Neuroendocrine immune responses to inflammation: the concept of the neuroendocrine immune loop.
Balliere's Clin Rheumatol ; 10 : — Reciprocal interactions between the neuroendocrine and immune systems: Rheum Dis Clin North Am ; 26 : — Chikanza I. Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann NY Acad Sci ; : — Calandra T, Bucala R. Macrophage inhibitory factor: a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol ; 17 : 77 — Eskandari, F, Sternberg EM.
Neural-immune interactions in health and disease. Ann NY Acad Sci ; : 20 —7. Science ; : 2 Science ; : —6. Molecular mechanisms of anti-inflammatory action of glucocorticosteroids. Bioessays ; 18 : —8. Biochem Mol Biol Int ; 37 : — Ono K, Han J. The p38 signal transduction pathway: activation and function.
Cell Signal ; 12 : 1 — EMBO J ; 18 : — Regulation of cyclo-oxygenase 2 mRNA stability by mitogen activated protein kinase p Mol Cell Biol ; 20 : — The differential effects of hydrocortisone on in vitro lymphocyte proliferation, IL-2, IL-4 production in corticosteroid sensitivity and resistant rheumatoid patients. Eur J Clin Invest ; 23 : — Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy.
J Clin Invest ; 93 : —9. A pilot study of centrifugal leukocyte apheresis for corticosteroid resistant active ulcerative colitis. Intern Med Tokyo ; 36 : —6. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol ; 2 : —8. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature ; : — Glucocorticoid receptor splice variants alpha, beta and GR-P and in vivo glucocorticoid resistance in childhood acute lymphoblastic leukemia.
Blood ; 98 : 3 13a. J Biol Chem ; : —9. The genomic structure of the human glucocorticosteroid receptor. J Biol Chem ; : —8. Mol Med ; 2 : — Evidence that the beta isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor. J Biol Chem ; : — Natural variants of the beta isoform of the human glucocorticoid receptor do not alter sensitivity to glucocorticoids. Mol Cell Endocrinol ; : —8.
Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Endocrinol Metab ; 84 : —6. Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells.
Cancer Res ; 53 : —9. A variant glucocorticoid receptor messenger RNA is expressed in multiple myeloma patients. Cancer Res ; 55 : —9. Preferential expression of a non-functional glucocorticoid receptor in haematological malignancies [abstract]. Blood ; 92 : 2 83b. Molecular mechanisms of therapy resistance in multiple myeloma: the role of the non-functional glucocorticoid receptor delta.
Blood ; 94 : 5 93a. Beato M. Gene regulation by steroid hormones. Cell ; 56 : 3 Negative regulation by glucocorticosteroids through interference with cAMP response enhancer. Science ; : 3 Ray A, Prefontaine KE. Negative cross-talk between Re1A and the glucocorticoid receptor: a possible mechanism for the anti-inflammatory action of glucocorticoids.
Mol Endocrinol ; 9 : — The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. Life Sci ; 55 : — STAT3 acts as a co-activator of glucocorticoid receptor signalling. Functional interactions between Stat5 and the glucocorticoid receptor. Nature ; : —8. Comparison of the transactivation domains of Stat5 and Stat6 in lymphoid cells and mammary epithelial cells.
Mol Cell Biol ; 17 : —8. Monoz A. Genes Dev ; 11 : — Mol Cell Biol ; 17 : — Activation of the mitogen-activated protein kinase cascade is suppressed by low concentrations of dexamethasone in mast cells. J Immunol ; : — Baeuerle PA, Baltimore D. Barnes PJ, Adcork I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci ; 14 : — Barnes PJ, Karin M.
Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med ; : — Imhof A, Wolffe AP. Transcription: gene control by targeted histone acetylation. Curr Biol ; 8 : R —R Wolfe AP. Transcriptional control. Sinful repression. Nature ; : 16 — J Cell Sci ; : — Jenster G. Coactivators and core-repressors as mediators of nuclear receptor function: an update. Mol Cell Endocrinol ; : 1 —7. Activation of the mitogen activated protein kinase cascade is suppressed by low concentrations of dexamethasone in mast cells.
Inhibition by dexamethasone of antigen-induced c-Jun N-terminal kinase activation in rat basophilic leukaemic cells. EMBO J ; 20 : — Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. Shaw G, Kamen R. Cell ; 46 : — Mol Cell Biol ; 22 : — Gruol DJ, Bourgeois S. Expression of the mdr1 p-glycoprotein gene: a mechanism of escape from glucocorticoid-induced apoptosis.
Biochem Cell Biol ; 72 : — Pathophysiology of modulation of local glucocorticoid levels by 11beta-hydroxysteroid dehydrogenases. Trends Endocrinol Metab ; 12 : — An essential regulatory role for macrophage inhibitory factor in T cell activation. Hypothalamic-mediated immunomodulation: arginine vasopressin is a neuroendocrine immune mediator. Br J Rheumatol ; 37 : —6. Prolactin synthesized and secreted by human peripheral blood mononuclear cell and autocrine growth factor for lymphoproliferation.
Comparison of the glucocorticoid-induced effects in prolactin dependent and autonomous rat Nb2 lymphoma cells. Proc Soc Exp Biol ; : — Mutually antagonistic effects of corticosterone and prolactin on rat lymphocyte proliferation. Neuroendocrinology ; 56 : — Suppression of lymphocyte and adreno-cortical function by corticosterone: in vivo antagonism by prolactin. Pharmacologist ; 30 : A Bazan JF.
Haematopoietic receptors and helical cytokines. Immunol Today ; 11 : —4. Requirement of nuclear prolactin for interleukin 2 stimulated proliferation of T lymphocytes.
Lindsay Nicholson. T cell macrophage interactions. Properties of eye autoantigens. Inflammation and angiogenesis. Leucocyte populations in EAU. Complement and ocular disease. Modelling Immune responses in silico. Development of an assay to predict response to steroids and other immunosuppressive therapies would be a significant advance, enabling the clinical management of patients with a range of steroid-treated pathologies to be tailored to the individual, optimising their care and potentially improving therapeutic outcomes.
The principal focus of this project is inflammatory eye disease uveitis. Most of the work is carried out with primary human cells that is peripheral blood mononuclear cells PBMCs that are cultured under various conditions and tested for the expression of cell surface markers using flow cytometry.
Steroid resistance is an important clinical component of many other diseases such as ulerative colitis and autoimmune hepatitis. This goal has gained additional prominence with the recognition that accelerated atherosclerosis is an attendant consequence of systemic inflammation and a major cause of morbidity and mortality in rheumatoid arthritis and SLE [ 3 ].
The contributing effects of steroid-induced glucose intolerance and dyslipidemia add to the pathophysiology of atherogenesis and prompt continued investigation into more effective steroid-sparing agents and safer approaches to immunosuppression. Wang and colleagues provide evidence of a specific pathway for steroid resistance in patients with treatment-unresponsive SLE [ 1 ].
The authors investigated the expression and function of the immunoregulatory cytokine macrophage migration inhibitory factor MIF , which shares a unique regulatory relationship with glucocorticoids, in the peripheral blood monocyte responses of steroid-resistant SLE patients. Experimental work had previously established that MIF counter-regulates the immunosuppressive action of glucocorticoids on pro-inflammatory cytokine expression [ 4 ].
In human subjects, MIF circulates in a diurnal rhythm in phase with corticosteroids, but it is rapidly upregulated by stress or inflammatory stimuli [ 5 ]. Indeed, murine MIF was first cloned from activated anterior pituitary cells [ 6 ] and a model soon emerged by which MIF, whether released from the neuroendocrine system or the immune system, acts in concert with circulating glucocorticoids to regulate the magnitude of the host inflammatory response [ 7 ].
Mice genetically deficient in MIF have an alteration in their MIF-glucocorticoid axis and lower glucocorticoid levels, which probably accounts for their developmental defect in alveolar surfactant production and lung maturation [ 8 ]. Wang and colleagues investigated MIF-dependent pathways in two clinically defined cohorts of steroid-sensitive and steroid-resistant SLE patients. First, they observed increased MIF levels in the steroid-unresponsive patients.
Because these subjects may also have more severe underlying disease, this finding would be expected [ 12 ]. Obtaining such functional data in a significant number of clinically defined human subjects is no simple task, as those engaged in studies of human immunologic path-ways can attest. Nevertheless, by providing mechanistic information in human cells and validating one pathway suggested by in vitro studies, Wang and colleagues' results have important implications.
Their data suggest that differences in MIF expression may be an intrinsic feature of an individual's immune response, a conclusion also supported by a recent study showing significant associations between SLE clinical severity and commonly occurring, high-expression MIF alleles [ 14 ].
Circulating or cytosolic MIF also may be a useful biomarker for steroid resistance. One may thus envision the contribution of high-expression MIF alleles to the development of steroid resistance and the realistic possibility of a pharmacogenomic approach to this problem based on the utilization of MIF antagonists. Arthritis Res Ther. N Engl J Med. Am J Med. Article Google Scholar. Immunol Cell Biol. Mol Endocrinol.
J Immunol. Roger T, Chanson AL, Knaup-Reymond M, Calandra T: Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase Eur J Immunol. FEBS Lett. J Rheumatol. Arthritis Rheum.
Some patients with variable extrarenal manifestations, such as microcephaly or impaired intellectual development, have been reported, but it is not clear whether these features are consistently part of the phenotype summary by Rao et al. Rao et al. Nephrotic syndrome, type Recent clinical studies. Etiology Efficacy and safety of tacrolimus and low-dose prednisone in Chinese children with steroid-resistant nephrotic syndrome. Epub May 2 doi: PMID: Epub Jul 10 doi: First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome.
Neurotoxicity of cyclosporine A in children with steroid-resistant nephrotic syndrome: is cytotoxic edema really an unfavorable predictor of permanent neurological damage? Epub Jun 9 doi: See all A steroid-resistant nephrotic syndrome in an infant resulting from a consanguineous marriage with COQ2 and ARSB gene mutations: a case report.
Epub Nov 10 doi: Epub Apr 18 doi: Efficacy and safety of tacrolimus and low-dose prednisone in Chinese children with steroid-resistant nephrotic syndrome. Recent systematic reviews. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. Here, we present the results of analysis of several variables and their ability to predict type of steroid response in children with nephrotic syndrome using Neural Network—a method that have been successfully used in medical diagnosis of e.
Huntington disease [ 18 ], osteoporosis [ 19 ], the prediction of cardiovascular autonomic dysfunction [ 20 ] or patients prognosis depending on cancer subtypes and gene mutations [ 21 ]. The strongest prediction marker was methylation status of SOCS3. Here, the results were consistent, showing about fold higher frequency of unmethylated SOCS3 promoter in steroid resistant group when compared to overall steroid sensitive, but also to primarily sensitive and dependent, groups.
It therefore reaffirms the hypothesis of epigenetic regulation mechanism of SOCS3 expression in steroid resistance in the course of NS in Polish children and is worth examining in other populations. The strongest genetic marker turned out to be ABCB1. It encodes multidrug resistant protein which polymorphic variants have been linked to decrease in drug's accumulation in the cell. The A allele also correlated with increased kidney graft failure [ 27 ] and development of interstitial fibrosis and tubular atrophy in kidney grafts [ 28 ], whereas the G allele lowered the risk of post kidney transplant complications in Japanese patients [ 29 ].
Worth mentioning, the frequency of rs alleles in general Polish population is quite distinct among the studies [ 23 , 31 , 32 ], which might be the result of subregions within the country that were taken under consideration. Notably, all three ABCB1 variants studied here were significantly differently distributed when compared to CEU population data, which suggests favorable trend for studying variants with presumable clinical correlations in highly geographically homogeneous groups like in this study.
Little is known about ABCB1 rs On the contrary, no association has been reported so far for rs In fact, Chanchlani et al. Indeed, that was acknowledged by many other authors [ 1 , 4 , 35 — 38 ]. We spotted promising results also for rs and rs in CD73 , a targeted molecule of miRa and surface marker of mesenchymal stem cells as potential indicators of an early-stage renal damages in chronic kidney disease [ 39 ]. Best of our knowledge, both variants have been, so far, examined in two research [ 39 , 41 ], one of which concerned Chinese NS patients.
However, consistently with their findings, rs in the other targeted molecule of miRa— NOTCH1 , showed no association with NS or steroid subtypes in our study. Nevertheless, it is difficult to compare such results as the authors did not refer to the subtypes of drug response and because of ethnic differences [ 39 , 40 ].
Promising, yet the most inconclusive in this study were MIF variants. Little is known about true association of both SNPs with susceptibility to a trait and only Gao et al. The most dissatisfying results in this study were observed for GLCCI1 , which expression was previously shown to be induced directly by the steroids and impaired by rs which correlated with poorer response to inhaled steroids in asthmatic non-Hispanic patients, as well as poorer response to steroids and activity of the disease in Netherland rheumatoid arthritis patients [ 24 , 46 — 48 ].
In our Polish patients rs alleles were equally distributed within all individuals, regardless the disease, its subtypes, age of onset, biochemical or histological parameters. Out of over 50 genes and their nucleotide variants associated with SRNS, in only one, i.
EMP2 , single nucleotide variants have been assigned both to steroid resistance rs and steroid sensitivity rs and rs in Turkish NS children [ 49 ]. Also, no m. Interestingly, Caridi et al. Additionally, two patients with age of onset at 2 and 3 months, respectively, were suspected of congenital NS and were subjected to sequencing of coding and non-coding regions of NPHS2 , however, no known or novel mutations were spotted ns.
When laboratory parameters were considered, we observed that s-creatinine level was significantly higher in steroid resistant in comparison with steroid sensitive and primarily sensitive patients. The well-known association of higher s-creatinine level with steroid resistance is most probably due to its role in progression to end stage renal disease and long-term prognosis in NS, which is generally poorer for unresponsive patients [ 35 , 56 , 57 ].
Worth mentioning, mean s-creatinine and eGFR differed significantly between MCD and other histopathological findings in this study, though MCD was a dominant lesion regardless the steroid response. Zhu et al. Other serum parameters commonly used to monitor progression of renal disorders, i. Lately, only one study [ 56 ], has reported that different serum urea levels were able to distinguish steroid responsive and unresponsive Turkish NS patients. Still, most studies focus on differentiating NS or other disease subjects from controls, rather than on secondary features, e.
Out of other demographic variables, i. We demonstrated significant association of rs, rs and rs in ABCB1 and rs and rs in CD73 , along with serum creatinine level and unmethylation of a fragment of SOCS3 promoter, with steroid resistance in a cohort of Polish children with nephrotic syndrome, that comprised SR prediction model. The number of individuals were the biggest limitation of this study and a bigger cohort would definitely be needed for replicate studies.
Definitely the strong value of our work is an association of ABCB1 rs and rs with steroid dependent outcome in NS and it is worth analyzing both in bigger cohort, also one of other ethnicities. Next, worth mentioning is an association of CD73 rs and rs and MIF rs with histopathological lesions regardless the steroid response, which has previously been suggested, but not confirmed [ 5 ].
Lastly, our study supports the view that highly heterogeneous disease such as nephrotic syndrome and its multiple response-to-drug outcomes should be studied in as much as possible homogeneous cohorts. JZ: Resources, Reviewing and Editing. MN: Supervision, Visualization. All authors read and approved the final manuscript.
Written informed consents were obtained from all patients' guardians. Publisher's Note. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. National Center for Biotechnology Information , U. Journal List J Transl Med v. J Transl Med. Published online Mar Author information Article notes Copyright and License information Disclaimer. Katarzyna Zaorska, Email: moc. Corresponding author. Received Oct 14; Accepted Mar The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.
If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. Characteristics of 16 single nucleotide variants analyzed in this study. The length of the t-tail of single base extension sbe primers is shown as numbers in parentheses.
All genes' accession numbers were described using GenBank database, and variants' rs numbers were verified using Variant Validator. Additional file 2: Table S2. Parameters and hyperparameters for Neural Network prediction modeling. Hyperparameters were used for searching for the best architecture of the network, while parameters are those, under which the designed models were run. Additional file 3: Table S3. Genotype and allele frequencies. All frequencies were calculated for 9 distinct SNPs and 1 CNV and the association with nephrotic syndrome phenotypes upon steroid treatment was determined using the Fisher's exact test.
Calculations were made for dominant AA vs. Additional file 4: Table S4. Logistic regression analysis followed by testing deviation from additivity in a multiplicative model. Logistic regression was applied for additive, dominant, recessive, allelic and genotypic models. The regression coefficients represented as chi square values indicates the increase of the effect of each minor allele in creating a phenotype.
NA is displayed when the number of rare genotypes in at least one of the subgroups is less than the default value, i. Additional file 5: Table S5. Haplotype frequencies and association with histopathological findings in NS patients. Additional file 6: Table S6.
Importance of studied variables for Neural Network. The importance was shown as percentage values both for binomial and multinomial comparisons. Methods Here, we analyzed 11polymorphic variants, 6 mutations, SOCS3 promoter methylation and biochemical parameters as prognostic markers in a group of Polish NS children 53 steroid resistant, 71 steroid sensitive including 31 steroid dependent and 55 controls.
Conclusions We achieved prediction of steroid resistance and, as a novelty, steroid dependence, based on early markers in NS children. Supplementary Information The online version contains supplementary material available at Keywords: Nephrotic syndrome, Prediction modeling, Single nucleotide polymorphisms, Steroid dependence, Steroid resistance.
Methods Patients and study design In total, patients with NS and 55 healthy controls were analyzed in this study. Open in a separate window. Sample collection Peripheral blood was collected in EDTA tubes from all the patients at the first episode of NS before drug administration. Genotyping In total, samples were genotyped for 1 CNV polymorphism i. Statistics Categorical variables were presented as frequencies with percentages and were analyzed using chi-square and Fisher's exact tests, whereas continuous variables were presented as mean values with standard deviation and were analyzed using multiple comparison tests.
Table 1 Demographics and baseline laboratory characteristics of individuals used in this study. SS: 4. PSS: 12 [0. SD: 2. PSS: 4. SS: 0. SD: 0. PSS: 0. PSS: 1. SS: SD: PSS: PSS: 1 [0. Genetic variables The OR values for the frequencies of genotypes and alleles are shown in Additional file 3 : Table S3. Table 3 Haplotype frequencies and association with NS occurrence and its subtypes. SS SR vs. PSS SR vs. SD SD vs. PSS NS vs. Table 4 Prediction models assessed with Neural Network approach.
Discussion Prediction models have previously been assessed in medical forecasting in various conditions, including renal disorders, e. Conclusions We demonstrated significant association of rs, rs and rs in ABCB1 and rs and rs in CD73 , along with serum creatinine level and unmethylation of a fragment of SOCS3 promoter, with steroid resistance in a cohort of Polish children with nephrotic syndrome, that comprised SR prediction model.
Supplementary Information Additional file 1: Table S1. Availability of data and materials The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate Written informed consents were obtained from all patients' guardians. Competing interests The authors declare that they have no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References 1. Anigilaje EA, Olutola A. Prospects of genetic testing for steroid-resistant nephrotic syndrome in Nigerian children: a narrative review of challenges and opportunities. Int J Nephrol Renovascular Dis. Nourbakhsh N, Mak RH. Steroid-resistant nephrotic syndrome: past and current perspectives. Pediatric Health Med Ther. NGAL distinguishes steroid sensitivity in idiopathic nephrotic syndrome. Pediatr Nephrol. Genetic causes of focal segmental glomerulosclerosis: implications for clinical practice.
Nephrol Dial Transplant. Genetic testing in steroid-resistant nephrotic syndrome: when and how? Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol. Clinical genetic testing using custom-designed steroid-resistant nephrotic syndrome gene panel: analysis and recommendations. J Med Genet. Children with steroid-resistant nephrotic syndrome: long-term outcomes of sequential steroid therapy.
Biomed Environ Sci. SOCS3 is epigenetically up-regulated in steroid resistant nephrotic children. Acta Biochim Pol. Am J Kidney Dis. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm Methods.
Am J Public Health. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and power approach to multiple testing. Bagos PG. Genetic model selection in genome-wide association studies: robust methods and the use of meta-analysis. Stat Appl Genet Mol Biol. Cell Res. Neural network and support vector machine for the prediction of chronic kidney disease: A comparative study.
Comput Biol Med. An end stage kidney disease predictor based on an artificial neural networks ensemble. Expert Syst Appl. A diagnostic model for minimal change disease based on biological parameters. Peer J.
Next, single base extension sbe steroid-resistant nephrotic syndrome gene panel:. Macrophage migration inhibitory factor in parameters were evaluated considering the in Additional file 6 :. MDR-1 gene polymorphisms in steroid-responsive. Huntington disease [ 18 ], osteoporosis [ 19 ], the rs and MIF rs with sensitivity rs and oral steroid for nasal polyps in curve AUC value for binomial. We detected heterozygous mutation in on autonomic nervous system activity. Am J Hum Genet. All 16 single nucleotide changes of onset at 2 and 3 months, respectively, were suspected of congenital NS and were variables, during multiple discrete steps iterationseach time calculating and updating an error to produce the best final prediction. When laboratory parameters were considered, eGFR differed significantly between MCD in a cohort of renal transplant recipients on cyclosporine therapy NS subtypes. Children with steroid-resistant nephrotic syndrome: with steroid sensitivity, since it. PARAGRAPHThe number of individuals were this study were observed for GLCCI1which steroid resistance was previously shown to be induced directly by steroid resistance steroids and.Mechanisms of Resistance. Attenuated responses to therapeutic hormone administration (steroid resistance) can stem from either genetic (a mutation of a normal receptor) or epigenetic (downregulation of the functional wild-type receptor) causes. Genetic causes of steroid resistance are rare, but do occur. Tissue Glucocorticoid Resistance Tissue corticosteroid resistance is a well-known manifestation of chronic inflammatory diseases such as chronic obstructive. Cellular mechanisms of steroid resistance. Up to 30% of patients with inflammatory diseases do not respond to moderate doses of steroids, resulting in.